Phase II Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-)

This study is currently recruiting participants.

Verified October 2010 by University of California, Irvine

Study NCT00618657 Information provided by University of California, Irvine

First Received on February 7, 2008. Last Updated on October 11, 2010 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Breast Cancer

Additional conditions recognized in this trial

Breast Neoplasms

More general conditions related to this trial

Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases

Interventions listed in this trial

Additional drug interventions recognized in this trial

Paclitaxel
Trastuzumab

More general drug interventions related to this trial

Sponsors listed in this trial